Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sodium/glucose cotransporter 1 (SGLT1) is a membrane protein responsible for the active transport of glucose and galactose into cells, primarily in the small intestine and kidney. It is encoded by the SLC5A1 gene and functions as an electrogenic symporter, coupling the transport of two sodium ions for each glucose molecule. SGLT1 plays a crucial role in dietary glucose absorption and renal glucose reabsorption, and mutations in SLC5A1 can cause congenital glucose-galactose malabsorption syndrome. It is indirectly targeted by drugs used in diabetes management and plays a key role in oral rehydration therapy.
Indirectly targeted by SGLT2 inhibitors, leading to increased SGLT1 activity in the intestine and kidney to compensate for reduced SGLT2 activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sodium Glucose Cotransporter 1 (SGLT1).